Detalhe da pesquisa
1.
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Oncologist
; 29(4): e514-e525, 2024 Apr 04.
Artigo
Inglês
| MEDLINE | ID: mdl-38297981
2.
A phase I study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors.
Clin Cancer Res
; 21(5): 1044-51, 2015 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-25388167
3.
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
Lancet Haematol
; 2(8): e339-46, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26688487
4.
Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothened inhibitor PF-04449913 in healthy volunteers.
Cancer Chemother Pharmacol
; 74(2): 411-8, 2014 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-24944041
5.
Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology.
Sci Transl Med
; 8(324): 324ps5, 2016 Feb 03.
Artigo
Inglês
| MEDLINE | ID: mdl-26843188
6.
Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
Cancer Res
; 71(4): 1362-73, 2011 Feb 15.
Artigo
Inglês
| MEDLINE | ID: mdl-21212415